-
Immunovaccine Prices Prospectus Offering
HALIFAX, NOVA SCOTIA--(Marketwire - Sept. 3, 2010) -
-
Technolas Perfect Vision laça duas inovações de procedimento laser pioneiros no XXVIII Congresso do ESCRS, Paris
Primeiro tratamento de catarata e refração com femtossegundo e novo tratamento excimer de presbiopia
-
Technolas Perfect Vision Unveils Two New Pioneering Laser Procedure Innovations at the XXVIII Congress of the ESCRS, Paris
First Cataract & Refractive Femtosecond Laser and New Excimer Treatment for Presbyopia
-
Technolas Perfect Vision revela dos procedimientos láser innovadores pioneros en el XXVIII Congreso de ESCRS, París
Primer láser femtosecond para cirugía de catarata y refractiva y nuevo tratamiento láser excimer para presbiopía
-
Bausch + Lomb to Acquire Miochol(R)-E
ROCHESTER, NY--(Marketwire - September 3, 2010) - Bausch + Lomb, the global eye health company, has announced that it has concluded its acquisition of a portion of the assets and intellectual property for Miochol®-E from Affiliates of Novartis AG. Bausch + Lomb intends to complete the acquisition of the remaining assets and intellectual property upon the necessary regulatory clearance.
-
Miraculins Announces Completion of PREVU Skin Cholesterol Test Acquisition
WINNIPEG, MANITOBA--(Marketwire - Sept. 3, 2010) - Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that it has completed the acquisition from PreMD Inc. of all assets relating to the PREVU* Skin Cholesterol Test. PREVU* is a simple, non-invasive, inexpensive test that addresses the major worldwide market of cardiovascular risk assessment. PREVU* has been cleared for sale in the US by the FDA (Food and Drug Administration). It has also received regulatory clearance for sale in Canada and Europe and was successfully test marketed in the US and Canada.
-
Pharmaceutical-Biotech Industry Maintains Balance With $2 Billion in Planned September Project Starts, an Industrial Info News Alert
SUGAR LAND, TX--(Marketwire - September 3, 2010) - Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- The million dollar question continues to be "... is the economy better, is it getting worse, or is it somewhere in between?" Theories abound, talking heads offer wildly varied opinions, while in regard to active capital investment, the facts can only be found in hard data. If holding steady is considered a positive thing, a recent survey of Industrial Info's Pharmaceutical Tracker -- Online Database has revealed solid good news in terms of project activity for the month of September. The sector is holding its own with slightly more than $2 billion in 47 expected project starts this month, almost dead even with the 2009 figure of $2.4 billion.
-
Agennix AG Announces Data From Talactoferrin Randomized, Double-Blind, Placebo-Controlled Phase II Trial in Severe Sepsis Presented at the Sepsis 2010 International Symposium
PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - September 3, 2010) - Agennix AG (FRANKFURT: AGX) (XETRA: AGX) announced that data from a Phase II trial with talactoferrin in severe sepsis were presented today at the Sepsis 2010 International Symposium, which was hosted by the International Sepsis Forum, in Paris, France. The double-blind, placebo-controlled trial evaluated talactoferrin versus placebo in 190 adult patients with severe sepsis enrolled at 25 leading centers across the U.S. As previously reported, the Phase II trial achieved its primary endpoint of a reduction in 28-day all-cause mortality from 26.9% in the placebo arm to 14.4% in the talactoferrin arm (two-tailed p-value adjusted for cardiovascular dysfunction = 0.05, odds ratio by logistic regression analysis = 0.48), a 46% relative reduc
-
Medline Launches New "Pink Pearl(TM)" Nitrile Exam Gloves Featuring Aloe Vera to Soothe and Moisturize Hands
Medline Will Donate $1.00 for Every Case Sold to the National Breast Cancer Foundation
-
Virtual Pharma Rep(TM) Partners With digitalDVM(TM) to Launch virtualVetRep(TM) for the Animal Health Industry
Virtual Pharma Rep(TM) E-Detailing Platform Brings a New Virtual Sales Approach to the Animal Health Industry
-
MedLink Announces Partnership With Healthcare Information Technology Provider Thrasys, Inc.
NEW YORK, NY--(Marketwire - September 2, 2010) - MedLink (OTCBB: MLKNA), a leading provider of Electronic Health Records and practice management solutions, today announced a partnership with Thrasys, Inc. a provider of next-generation health information technology and solutions. MedLink and Thrasys have collaborated to provide interoperability and health record management based on SyntraNet from Thrasys, a cloud based Health Information Exchange (HIE) and Collaboration Network. SyntraNet enables more efficient and coordinated care across healthcare communities.
-
New Lab Opens in Lesotho With Support From Association of Public Health Laboratories
SILVER SPRING, MD--(Marketwire - September 2, 2010) - A new laboratory, designed and built in accordance with international guidelines, opened September 1 in Maseru, Lesotho. The Makoanyane Military Hospital Laboratory now offers an expanded testing menu, including CD4 and Acid Fast Bacilli microscopy, and separate rooms dedicated to specimen reception, microbiology, chemistry, hematology and CD4 testing. The formerly limited, one-room hospital lab was transformed through a collaborative effort of The US Department of Defense and CDC's Global AIDS Program to support the Lesotho Defense Force's facility.
-
Bilcare AG Successfully Completes the Acquisition of INEOS' Global Films Business
PUNE, INDIA--(Marketwire - September 2, 2010) - Bilcare AG, part of the Bilcare group, today successfully completed all formalities related to the acquisition of the global films business from the INEOS Group. Bilcare AG had announced its intentions to acquire the business for a sum of Rs. 607 crores on August 2, 2010.
-
Cell Publishes on the Critical Role of Metals in Alzheimer's Disease
New Evidence Strongly Supports Prana's Therapeutic Strategy to Regulate Brain Metals
-
Eurand to Participate in Upcoming Investor Conferences
PHILADELPHIA, PA--(Marketwire - September 2, 2010) - Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, is scheduled to participate in the following upcoming investor conferences:
-
Antisoma Annual Report and Accounts 2010
LONDON--(Marketwire - September 2, 2010) -
-
SDA (Stearidonic Acid) Soybean Oil Increases the Omega-3 Index: Study Published in The American Journal of Clinical Nutrition
SDA Soybean Oil Is a Plant-Based Omega-3 That Efficiently Converts to Heart-Healthy EPA in the Body
-
Xylitol Canada Strategic Partnership Now Includes Mascoma Corporation
Company Provides Corporate Update on Recent Sale of SunOpta BioProcess Inc. to Mascoma Corporation
-
Daxor Announces Third Quarter Dividend and Update on Use of Blood Volume Analyzer in Heart Failure
NEW YORK, NY--(Marketwire - September 2, 2010) - Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced that the Board of Directors has voted to declare a dividend of $0.25 per share. The dividend will be paid to shareholders of record as of Wednesday, September 15, 2010. The dividend will be paid on Thursday, September 30, 2010.
-
Metiscan Discusses Revolutionary Technologies for $80B Convention, Trade Show and Meeting Industry, Digital Medical Information, Financial Highlights and More During Nationwide Teleconference
DALLAS, TX--(Marketwire - September 2, 2010) - Metiscan, Inc. (PINKSHEETS: MTIZ) announced today shareholder points of interest discussed during the Company's nationwide teleconference yesterday. Mr. Bryan A. Scott, President & CEO, and Mr. Brian Hart, COO of Metiscan, provided deeper insight into its subsidiaries' markets, products, and near term objectives, as well as Metiscan's pursuit in listing on the OTCBB.
-
BioExx Announces Closing of Over Allotment Option
TORONTO, ONTARIO--(Marketwire - Sept. 2, 2010) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
-
Peregrine to Report First Quarter Fiscal Year 2011 Financial Results After Market on September 9, 2010
TUSTIN, CA--(Marketwire - September 2, 2010) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the first quarter fiscal year 2011 on September 9, 2010 after market and will host a conference call and webcast at 4:30 p.m. EDT (1:30 p.m. PDT). Peregrine's senior management will discuss financial results for the first quarter ended July 31, 2010 of fiscal year 2011 and will review its clinical development programs.
-
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction Film Product
SAINT LAURENT, QUEBEC--(Marketwire - Sept. 2, 2010) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") today announced the completion of a pilot study that indicates that IntelGenx has successfully developed a novel oral film, INT007, that is bioequivalent to a leading branded tablet containing a phosphodiesterase type 5 (PDE-5) inhibitor for the treatment of erectile dysfunction. INT007 has been developed using IntelGenx' proprietary immediate release "VersaFilm" drug delivery technology.
-
Pharming Clears 2010 Private Bond Debt
LEIDEN, NETHERLANDS--(Marketwire - September 2, 2010) - Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that
it has
converted all of the remaining January 2010 bonds. The current
number of
outstanding shares as per today is 355,781,497 from 347,979,345 at
August
24, 2010.
-
MorphoSys Initiates Program Against Drug-Resistant MRSA Infections
MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - September 2, 2010) -
-
Addex drug-candidate effective in Alzheimer's disease model
GENEVA, SWITZERLAND--(Marketwire - September 2, 2010) -
-
Epistem Announce Agency Agreement With Veritas Japan
MANCHESTER, UNITED KINGDOM--(Marketwire - Sept. 2, 2010) - Epistem plc (LSE:EHP), the UK biotechnology company, announced today that its Contract Research Services division has entered into an agreement with the Veritas Corporation to exclusively market and distribute Epistem's scientific research services in Japan.
-
Pyng Medical Corp. Receives US FDA 510(k) Clearance for FASTx(TM)
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 1, 2010) - Pyng Medical Corp. (TSX VENTURE:PYT) announces today that it has received 510(k) clearance from the US FDA to market the FASTxT Sternal Intraosseous Device. The company will now begin ramping up production to meet the anticipated demand for this next generation IO product.
-
Novadaq Signs North American Marketing and Sales Agreement With LifeCell
LifeCell to Distribute SPY in Plastics, GI and Head and Neck Surgery
-
Elan Shareholder to Host Conference Call on September 8, 2010 at 10:00 AM EDT to Introduce Potential Board Members
COPENHAGEN, DENMARK--(Marketwire - September 1, 2010) - Ib Sønderby, CEO of Zoar Invest and a stockholder of Elan Corporation, plc (NYSE: ELN), today announced that a conference call will be hosted on September 8, 2010 at 10:00 a.m. Eastern Daylight Time to introduce four potential Directors for the Elan Board and to discuss the current state of the Company. The call will be accompanied by a slide-show presentation, which will be available for download 15 minutes prior to the start of the call at www.SaveElan.com. A brief Q&A session will follow the prepared remarks.
-
Theravance to Present at Investor Conferences in September 2010
SOUTH SAN FRANCISCO, CA--(Marketwire - September 1, 2010) - Theravance, Inc. (NASDAQ: THRX) announced today that its Chief Executive Officer, Rick E Winningham, is scheduled to present at the following investor conferences in September 2010:
-
enGene Adds Leading Nanomedicine Expert To Scientific Advisory Board
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 1, 2010) - enGene Inc., a privately held biotechnology company developing an innovative platform technology to deliver nucleotides (DNA or siRNA) to mucosal tissue for treating a variety of diseases, including inflammatory bowel disease (IBD) and diabetes, announced today that Dr. Russell J. Mumper has joined the Company's Scientific Advisory Board.
-
Alzheimer's Therapeutics Reviewed by NeuroInvestment
CARDIFF, CA--(Marketwire - September 1, 2010) - NI Research has released the September issue of NeuroInvestment, which features a comprehensive review of Alzheimer's therapeutics, and a critical assessment of the pharma industry's premature rush to closure:
-
New Data Will Help Predict Vision Loss in Glaucoma
September 2010 Ophthalmology Journal Reports Rotterdam Study Update
-
Skystar Bio-Pharmaceutical to Present at Rodman & Renshaw Annual Global Investment Conference
XI'AN, CHINA--(Marketwire - September 1, 2010) - Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference at The Palace Hotel in New York City on September 13, 2010 at 2:25pm Eastern time.
-
MorphoSys to Present at Three Investor Conferences in September
MARTINSRIED, GERMANY and MüNCHEN, GERMANY--(Marketwire - September 1, 2010) - MorphoSys AG
/ MorphoSys to Present at Three Investor Conferences in September processed
and transmitted by Hugin AS. The issuer is solely responsible for the
content of this announcement.
-
Ambrilia Biopharma Provides Bi-Weekly Update on its Status
Attention Business/Financial/Health Editors
-
Ambrilia Biopharma dépose son rapport bi-hebdomadaire sur la situation
Attention directeurs des rubriques affaires/finance/santé
-
International Drug & Explosives Detection Company IDenta Corp. in Negotiations With Another Retail Chain Store
JERUSALEM--(Marketwire - September 1, 2010) - IDenta Corp. (PINKSHEETS: IDTA) CEO Yaacov Shoham announced today that the company has recently started negotiations with another chain store to sell the General Screening drug detector at their chain store locations. This new chain store is not one of the eight stores originally announced (published at May 28, 2009) but these negotiations are a direct result of the 70,000 kit order received from the other larger chain store.
-
Equity Research on GlaxoSmithKline and Abbott Laboratories - The Emerging Markets Opportunities
JOHANNESBURG, SOUTH AFRICA--(Marketwire - September 1, 2010) - www.stockcall.com/ offers investors comprehensive research on the major drug manufacturers industry and has completed analytical research on GlaxoSmithKline (NYSE: GSK) and Abbott Laboratories (NYSE: ABT). Register with us today at www.stockcall.com/ to have free access to these researches.
-
Theratechnologies est heureuse d'annoncer la nomination d'un nouveau président et chef de la direction
MONTRÉAL, CANADA--(Marketwire - 1 sept. 2010) - Theratechnologies (TSX:TH) a annoncé aujourd'hui la nomination de monsieur John-Michel T. Huss à titre de président et chef de la direction de la Société. M. Huss entrera en fonction dans les prochains mois.
Jusqu'à tout récemment, M. Huss agissait à titre de chef de cabinet auprès du bureau du chef de la direction de Sanofi-Aventis, à Paris. M. Huss possède plus de 20 ans d'expérience dans l'industrie pharmaceutique. Il a occupé plusieurs postes à l'échelle internationale et a été responsable de portefeuilles de produits diversifiés, incluant le diabète et les troubles du métabolisme. M. Huss a commencé sa carrière en 1990, chez Merck & Co., Inc, principalement aux ventes
-
Theratechnologies is Pleased to Announce the Appointment of a New President and CEO
MONTRÉAL, CANADA--(Marketwire - Sept. 1, 2010) - Theratechnologies (TSX:TH) announced today the appointment of Mr. John-Michel T. Huss as President and Chief Executive Officer of the Company. Mr. Huss will assume his responsibilities in the coming months.
Until recently, Mr. Huss was Chief of Staff, Office of the CEO, of Sanofi-Aventis in Paris. Mr. Huss has over 20 years experience in the pharmaceutical industry in various international positions and was responsible for various disease areas including diabetes and metabolism. Mr. Huss began his career in 1990, at Merck & Co., Inc. primarily in sales and marketing in the U.S., Germany and Switzerland. In 1996, he was offered a position with F. Hoffman-La Roche as an Internal Product Manager at their Basel headquarters in Switzerland. In 1999, he joined Sanofi-Synthélabo
-
UV Flu Technologies UV-400 Generating Excitement in the Air Purifier Marketplace
Persistent Odor and VOC Reduction Capability Gets Favorable Response
-
Stem Cell Industry Leader Dwight Brunoehler Named President of AmStem Corp.
Says Regenerative Medicine Is the Future of Stem Cell Science and AmStem Is Leading the Way
-
InoLife Technologies, Inc. to Market a Plavix Metabolizing Test to the Medical Industry
DNA Test Enables Physicians to Predict Medication Response in Patients for Effective Treatment
-
Insulet Corporation to Present at Upcoming Investor Conferences
BEDFORD, MA--(Marketwire - September 1, 2010) - Insulet Corporation (NASDAQ: PODD), the leader in tubing-free insulin pump technology with its OmniPod® Insulin Management System, today announced the Company will participate in several upcoming investor conferences. These conferences include:
-
Molecular Insight Receives Eighth Extension of Waiver Agreement With Bond Holders
CAMBRIDGE, MA--(Marketwire - September 1, 2010) - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology, today announced that the Company has received an eighth extension of its waiver agreement with its Bond holders, allowing debt restructuring discussions to progress.
-
Yeast Protein Extraction Kit From Protein Discovery for Whole Proteome Analysis
KNOXVILLE, TN--(Marketwire - September 1, 2010) - Protein Discovery today announced that they have extended their protein extraction kit product line by launching the YPX Yeast Protein Extraction Kit. Unlike other yeast protein extraction products, the YPX kit does not use mechanical disruption to break open the tough cell walls of yeast. Using the YPX kit is much faster than carrying out conventional yeast lysis procedures used for protein extraction, and total protein yield is higher. The YPX kit protocol is simple and economical, and therefore offers substantial usability and cost benefits to researchers who wish to carry out experiments on many yeast cultures simultaneously. Finally, the YPX Yeast Protein Extraction Kit extracts the entire yeast proteome with nearly complete efficiency, and is uniquely compatible with quantitative yeast proteomics workflows which would otherwise be complicated by day-to-day and lab-to-lab variations in protein extraction efficiencies.
-
Yasheng Group Common Stock Begins Trading on the OTCQB Stock Market
REDWOOD CITY, CA--(Marketwire - September 1, 2010) - Yasheng Group (OTCQB: YHGG), is pleased to announce that its shares of common stock are now being quoted on the OTCQB as a U.S. registrant, a market tier for OTC stocks reserved for companies which are fully reporting to the Securities and Exchange Commission.
-
Functional Technologies Reports Positive Results of Novel Malaria Treatment Trials
Yeast neutralizes malarial parasites in mice without side effects
-
Auxilium Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference and the Stifel Nicolaus Healthcare Conference
MALVERN, PA--(Marketwire - September 1, 2010) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that executive management will participate in the following investor conferences:
-
Spencer Pharmaceutical Widens Patent Protection to Address the Growing Epidemic in Diabetes Globally
BOSTON, MA--(Marketwire - September 1, 2010) - Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announces that as a direct result of its recent very positive lab findings, it has moved forward to widen the Patent Filing for Global Patent Protection.
-
QIAGEN Launches New Automated Modular Testing Platform for Molecular Diagnostics
HILDEN, GERMANY and GERMANTOWN, MD--(Marketwire - September 1, 2010) -
-
Aegis' ProTek(R) Excipients Prevent Aggregation and Eliminate Unwanted beta-Interferon Immunogenicity
SAN DIEGO, CA--(Marketwire - September 1, 2010) - Recombinant human beta-interferon reduces the frequency of multiple sclerosis (MS) exacerbations and improves MS outcome measures. Unfortunately, current beta-interferon drug products form aggregates that provoke a neutralizing antibody response in MS patients, significantly reducing the effectiveness of the drug.
-
Ceapro Announces Granting of Stock Options
EDMONTON, ALBERTA, CANADA--(Marketwire - Aug. 31, 2010) - Ceapro Inc. (TSX VENTURE:CZO) today announced the granting of stock options to its directors, officers and certain employees for a total of 650,000 stock options, each with an exercise price of $0.10. Each grant vests in three equal instalments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant. Each option is exercisable, once vested, for a period of five years from the date of grant.
-
Alliance for the Prudent Use of Antibiotics Advises the FDA Needs to Establish a System to Monitor Use of Antibiotics in Food Animal Production
APUA President Says Mass Use of Antibiotics Is Cause for Concern
-
MethylGene nomme Dr Martin Godbout président de son conseil d'administration
MONTRÉAL, QUÉBEC--(Marketwire - 31 août 2010) - MethylGene Inc. (TSX:MYG) annonce aujourd'hui la nomination de Dr Martin Godbout au poste de président du conseil d'administration de la Société, qui prend effet immédiatement. Dr Godbout est membre du conseil d'administration de MethylGene depuis 2002. À ce jour, le conseil compte sept membres.
-
MethylGene Appoints Dr. Martin Godbout as Chairman of the Board of Directors
MONTREAL, QUEBEC--(Marketwire - Aug. 31, 2010) - MethylGene Inc. (TSX:MYG) today announced the appointment of Dr. Martin Godbout as Chairman of the Board of Directors of the Corporation, effective immediately. Dr. Godbout has been a member of MethylGene's Board of Directors since 2002. MethylGene's Board now numbers seven.
-
Micro Identification Technologies (MIT): Independent Testing, Manufacturing, Sales and Financing Goals Converge
SAN CLEMENTE, CA--(Marketwire - August 31, 2010) - Micro Identification Technologies, Inc. (OTCBB: MMTC) is a California-based public company that has developed, patented and produces a rapid microbial identification (ID) System that revolutionizes the bacteria ID process and can annually save thousands of lives and tens of millions of healthcare dollars. The MIT 1000 System identifies bacteria in minutes, not days, and at significant cost per test savings when compared to any conventional method -- it is not reliant on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis -- requiring only clean water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3 billion -- having expanded at a rate of 9.2 percent annually since 1998. Current growth projections are at 10.2
-
Healthcare Reform Law May Boost Biologic Treatments
NEW YORK, NY--(Marketwire - August 31, 2010) - Somewhat hidden in the healthcare reform legislation that passed this spring was a tax credit and exclusivity extension for biologic drug developers, which, according to healthcare market research publisher Kalorama Information, may have a long-term impact on the market for cancer treatments. Kalorama predicts $25 billion to be earned from newly developed cancer treatments in the next five years, many of which will be biologics, according to its report "World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)."
-
Theralase Laser Technologies Announces Q2 Financials
TORONTO, ONTARIO--(Marketwire - Aug. 31, 2010) - Theralase Technologies Inc. (TSX VENTURE:TLT) announces its second quarter 2010 financials.
-
Fly for MS to Embark on a Record-Making 60-Day, 29,000-Mile Trans-Atlantic Journey for Multiple Sclerosis Awareness
Fly for MS Is the Largest Scale MS Event Ever Organized and the Longest Humanitarian Flight Ever Undertaken
-
VIVALIS PUBLISHES ITS RESULTS FOR THE FIRST HALF AND CONFIRMS 2010 TARGETS
NANTES, FRANCE--(Marketwire - August 31, 2010) - VIVALIS (NYSE Euronext: VLS), a biopharmaceutical company, today announced its consolidated accounts (IFRS) for the first half of 2010 ended June 30, as well as its strategic perspectives.
-
New Report on Point of Care Diagnostic Market
ROCKVILLE, MD--(Marketwire - August 31, 2010) - MarketResearch.com has announced the addition of TriMark Publications's new report "Point of Care Diagnostic Testing World Markets," to their collection of In Vitro Diagnostics market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2718862
-
Media, Sera, & Reagent Market to Reach 3.8 Billion by 2015
-
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, SWEDEN--(Marketwire - August 31, 2010) -
-
NIAID Grant to Fund Dynavax Research on Hepatitis B Vaccination and Individual Variations in Human Responsiveness
BERKELEY, CA--(Marketwire - August 31, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today a grant from the National Institute of Allergy and Infectious Diseases (NIAID) to take a systems biology approach to study the differences between individuals that do or do not respond to vaccination against the Hepatitis B virus. This study will be one of several projects covered in a five-year, $17.6 million grant to Dr. Jacques Banchereau of the Baylor Institute of Immunology Research in Dallas as part of the Human Immune Phenotyping Centers program.
-
NanoInk Launches New Web Site
Contains Updated Information on the Company's Five Operating Divisions
-
Sunshine Heart Announces First Minimally Invasive Thoracotomy Procedures Performed for the C-Pulse(R) Heart Assist System
Saint Luke's Mid America Heart and Vascular Institute in Kansas City Successfully Implants Innovative Heart Failure Therapy through a Small Incision
-
A5 Laboratories Inc. Completes Validation of CRO Equipment
MONTREAL, QUEBEC--(Marketwire - Aug. 31, 2010) - A5 Laboratories Inc. (A5 Labs) (OTCBB:AFLB) today announced the CRO team headed by Dr. Matni has completed the validation of the first set of equipment that will be used for the testing of pharmaceutical raw materials and finished products. The company expects to complete the validation of the all remaining CRO equipment by the end of September 2010. Consequently the company plans to finalize its CRO testing and analytical standard operating procedures (SOPs) in October 2010.
-
Radient Pharmaceuticals Resumes Collaboration to Advance Its Onko-Sure(R) In Vitro Diagnostic Cancer Test in the USA
TUSTIN, CA--(Marketwire - August 31, 2010) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has resumed collaborations with Mayo Collaborative Services, Inc. to conduct a clinical study for the validation of RPC's US FDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test as a useful tool in colorectal cancer (CRC) recurrence and treatment monitoring.
-
Sensible Seeds Incredible Galactic Offer of 20% Off Selected Royal Kush Seeds
EDINBURGH, UNITED KINGDOM--(Marketwire - Aug. 31, 2010) - With economic times proving very tough for the best of us, any opportunity to save is like a shining beacon of hope in a storm, especially when looking for something special. Sensible Seeds only brings you special items, so when they have something extra to shout about you know you need to sit up and pay attention. The galactic opportunity for you today is a hefty 20% off the price of one of its finest strains of cannabis seeds.
-
Niusule Biotech Corp. Announces Strategic Distribution Agreement With China's Largest Drug Chain Store China Nepstar
MONROVIA, CA--(Marketwire - August 31, 2010) - Niusule Biotech Corp. (OTCBB: NIUS) (the Company), a fast-growing, China-based bio-pharmaceutical company focusing on animal-health products and human nutraceutical supplements, today announced that it has signed a distribution agreement with China Nepstar Chain Drugstore Ltd, China's largest retail drugstore chain based on the number of directly operated stores.
-
D. Medical Reports Second Quarter 2010 Financial Results
TIRAT CARMEL, ISRAEL--(Marketwire - Aug. 31, 2010) - D. Medical Industries Ltd. (NASDAQ:DMED)(TASE:DMDC) ("D. Medical"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, today announced financial results for the three and six months ended June 30, 2010. The unaudited selected consolidated financial statements presented below were prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). A convenience U.S. dollar translation of NIS amounts is provided using the rate of NIS 3.875 to US$1.00, the representative rate of exchange as of June 30, 2010 as published by the Bank of Israel.
-
Pacgen Reports First Quarter Financial Results
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 30, 2010) - Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE:PGA) reported financial results from its first quarter ended June 30, 2010 ("Q1 2011"). Unless specified otherwise, amounts are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles ("Canadian GAAP").
Results of Operations
-
Lorus Therapeutics Reports Results for Fiscal Year 2010
TORONTO, ONTARIO--(Marketwire - Aug. 30, 2010) - Lorus Therapeutics Inc. (TSX:LOR)(OTCBB:LRUSF) ("Lorus" or the "Company") a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for twelve months ended May 31, 2010. Unless specified otherwise, all amounts are in Canadian dollars.
-
Lorus Therapeutics Announces Proposed Rights Offering and Financing Commitment
TORONTO, ONTARIO--(Marketwire - Aug. 30, 2010) - Lorus Therapeutics Inc. (TSX:LOR)(OTCBB:LRUSF) ("Lorus" or the "Company") today announced that due to unfavorable market conditions the board of directors of Lorus has decided that the Company will not be proceeding with its previously announced public equity offering. In lieu thereof Lorus is intending to do a shareholder rights offering.
-
Pyng Medical Reports Third Quarter 2010 Financial Results
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 30, 2010) - Pyng Medical Corp. (TSX VENTURE:PYT) today announced it's financial and operating results for the three months ended June 30, 2010. All amounts are in Canadian dollars unless stated otherwise.
-
Neurotech Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial for AAD-2004, a Potent Spin Trapping Molecule and Microsomal Prostaglandin E Synthase-1 Inhibitor, Targeting Alzheimer's, Parkinson's, and Lou Gehrig's Disease
SUWON, SOUTH KOREA--(Marketwire - August 30, 2010) - Neurotech Pharmaceuticals Co., Ltd. has begun dosing in the Phase 1 clinical testing of AAD-2004. AAD-2004 was developed as a dual function drug to remove free radicals and PGE2, the key mediators of nerve injury in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The Phase 1 clinical trial was initiated to evaluate the safety, tolerability, and pharmacokinetics of AAD-2004 in healthy volunteers in April, 2010. The first two cohorts of the clinical study have been successfully completed without serious adverse events.
-
ForceLogix Technologies Inc. Announces Filing of Interim Financial Statements and Management's Discussion and Analysis
CHICAGO, IL--(Marketwire - August 30, 2010) - ForceLogix Technologies Inc. (TSX-V: FLT) is pleased to announce that it filed its interim financial statements and Management's Discussion and Analysis today for the quarter ended June 30, 2010. The financial statements are available for review on SEDAR, www.sedar.com.
-
CLSI and APHL Announce New Teleconference on Point-of-Care Glucose Devices
WAYNE, PA--(Marketwire - August 30, 2010) - The Clinical and Laboratory Standards Institute (CLSI) and Association of Public Health Laboratories (APHL) are offering a teleconference to the health care community to learn more about the different considerations surrounding acceptance criteria on point-of-care (POC) glucose devices. The teleconference on September 30 is titled "POC Glucose Devices: Perspectives From the Hospital, Government, and Vendor."
-
Autism Treatment Center of America Releases Video Documenting Son-Rise Program Journey Out of Autism
SHEFFIELD, MA--(Marketwire - August 30, 2010) - The Autism Treatment Center of AmericaT is pleased to announce another amazing before-and-after video documenting Oscar's journey out of Autism using The Son-Rise Program. The video is available at http://www.youtube.com/watch?v=kXpf4hwO860, and includes Oscar's autistic behaviors, his achievements in The Son-Rise Program playroom, and his turnaround behavior as a socially active and verbal child. Oscar's parents credit his transformation to The Son-Rise Program, which they implemented after taking The Son-Rise Program Start-Up at The Autism Treatment Center of America in Sheffield, Massachusetts.
-
myMatrixx(R) Announces Agreement With International Solutions
International Solutions Selects 1Click Ancillary(TM) as the Backbone of Its Ancillary Medical Services Needs
-
Taglich Brothers Initiates Coverage on BioCurex, Inc.
-
Pharmacogenomics Offers New Opportunities in the Molecular Diagnostics Field
ROCKVILLE, MD--(Marketwire - August 30, 2010) - MarketResearch.com has announced the addition of Business Insights's new report "The Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities in Personalized Medicine" to their collection of Molecular Diagnostics market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2729698
-
Novora BioMedical Corporation(TM) Announces Launch of 100% Natural Mouth Rinse
TORONTO, ONTARIO--(Marketwire - Aug. 30, 2010) - Novora BioMedical CorporationT ('NovoraT' or the 'company') announced that it has acquired the exclusive rights for a unique 100% natural mouth rinse that contains 84% certified organic ingredients. The rinse, called "100% Natural" is manufactured for the company on an exclusive basis for distribution to the professional dental market.
-
BioServe Introduces the BioServe Network
Network of Leading Biobanks Gives Researchers Unprecedented Access to Highest Quality Biosamples From Most Major Diseases
-
Henrik Lund MD Ph.D, Former Global VP in Clinical Development at Astra Zeneca, Named New CEO of Bionor Pharma ASA
OSLO, NORWAY--(Marketwire - August 30, 2010) - Bionor Pharma (OSLO: BIONOR) today announced that Henrik Lund MD Ph.D, will take over the position of CEO from Trond Syvertsen effective from 1 September 2010.
-
Two Thirds of Study Volunteers Respond to First-Ever "Re-Vaccination" of Vacc-4x, Bionor Pharma's Peptide-Based Therapeutic HIV-Vaccine
OSLO, NORWAY and WASHINGTON, DC--(Marketwire - August 30, 2010) -
-
Patient Recruitment Demographics Help Drive 72% of Companies' Clinical Strategies
"Know the Patient" Strategies Lay the Groundwork for Clinical Recruitment and Retention Success, Says Cutting Edge Information
-
Global Insulin Pumps Market to Reach $1 Billion by 2016
ROCKVILLE, MD--(Marketwire - August 30, 2010) - MarketResearch.com has announced the addition of GlobalData's new report "Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016" to their collection of Medical Devices market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2750464
-
SOHM India Boosts Generic Pharmaceutical Marketing Program With up to 60 Field Staff and Sales Associates Covering India's Most Populated States
BUENA PARK, CA--(Marketwire - August 30, 2010) - SOHM, Inc. (PINKSHEETS: SHMN) announced today its generic pharmaceutical marketing program received a significant boost with up to 60 field staff and sales associates covering India's most populated states. The Company started its marketing initiative in the largest state of India, Uttar Pradesh, last year and it has been a huge success producing repeat orders, increasing the Company's market share in India and generating record revenue. SOHM's private label generic drugs are economically priced and being well received by consumers and the medical community in India.
-
PharmaGap Announces Closing of First Tranche of Private Placement
OTTAWA, ONTARIO--(Marketwire - Aug. 30, 2010) - PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") announced today that it has completed the initial tranche of an offering of equity units (the "Units") previously announced on August 11 of up to $3 million. A total of up to 16,666,667 units are being made available to subscribers at the offering price of $0.18. Each Unit consists of one common share and one warrant to purchase a common share at an exercise price of $0.25 for the first two years and $0.35 for the third year of the three year warrant term.
The initial closing is in the amount of $493,077 being 2,739,317 Units, to accredited investors.
-
Research Reports on Mylan and Watson Pharmaceuticals - Generic Drug Makers Striving Successfully
JOHANNESBURG, SOUTH AFRICA--(Marketwire - August 30, 2010) - www.RothmanResearch.com provides members a complete scrutiny of the drugs -- generic industry with thorough research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Sign up now on www.rothmanresearch.com to access these free reports.
-
Marina Biotech Announces Allowance of Fundamental RNAi Delivery Patent From U.S. Patent Office
Patent Allowance Protects Marina Biotech Key Delivery Technology for RNAi Therapeutics
-
Stem Cell Therapeutics Corp. Announces Funding of the Traumatic Brain Injury (TBI) Clinical Study and Issuance of Stock Options
CALGARY, ALBERTA--(Marketwire - Aug. 30, 2010) - Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) wishes to announce budgetary approval of the SCT-sponsored investigator-lead Phase IIa study entitled "A Phase IIa, Single Center, Open Label Study to Characterize the Safety of Human Chorionic Gonadotrophin (hCG) and Epoeitin Alpha (EPO) in Traumatic Brain Injury". After strategic discussions between management and the Board of Directors a decision was made to go forward with the TBI clinical study. SCT will provide the funding necessary to complete the enrollment of 10 TBI patients in a single center open label study, lead by Dr. David Zygun, to characterize the safety of hCG and EPO in traumatic brain injury. A series of efficacy endpoints are part of the trial design in order to access various aspects of neurological status.
-
King Pharmaceuticals Appoints Jeffrey Bailey Chief Commercial Officer
BRISTOL, TN--(Marketwire - August 30, 2010) - King Pharmaceuticals, Inc. (NYSE: KG) announced today the appointment of Jeffrey A. Bailey to the position of Chief Commercial Officer. Mr. Bailey will be responsible for the Company's commercial activities in the branded pharmaceutical business and will lead all Sales, Marketing, Managed Care, Sales Operations and Business Analytics. Importantly, he will lead King's strategic mission to be the leader in the effective and responsible treatment of pain. Mr. Bailey brings a wealth of experience in the pharmaceutical industry, most recently serving in a general management capacity for a significant profit center at Novartis and serving on the Novartis North American Executive Committee. Mr. Bailey has also held senior leadership roles for a private equity firm and for Johnson & Johnson where he was responsible for managing products in the pain therapeutic category and for
-
Niusule Biotech Corporation to Present at the Rodman & Renshaw 2010 Annual Global Investment Conference
MONROVIA, CA--(Marketwire - August 30, 2010) - Niusule Biotech Corp. (OTCBB: NIUS) (the Company), a fast growing China-based bio-pharmaceutical company focusing on animal-health products and human nutraceutical supplements, today announced they will present at the Rodman & Renshaw 2010 Annual Global Investment Conference. The conference will be held September 12-15, 2010, at The New York Palace Hotel.
-
Novo Nordisk A/S - Share repurchase programme
BAGSVæRD, DENMARK--(Marketwire - August 30, 2010) -
-
RightSmile(R), the Leader in Cosmetic Teeth Whitening, Opens 10 New SmileShoppes Adding to Revenue
PORT ST. LUCIE, FL--(Marketwire - August 30, 2010) - RightSmile, Inc. (PINKSHEETS: RIGH) (www.RightSmile.com), the leader in Cosmetic Laser Teeth Whitening, announces the opening of 10 new SmileShoppes in August, adding $5,000 a month in reoccurring revenue.
-
IntelGenx and RedHill Announce Definitive Agreement for Anti-Migraine Film Product
SAINT LAURENT, QUEBEC--(Marketwire - Aug. 30, 2010) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") and RedHill Biopharma Ltd., an Israeli corporation ("RedHill") today announced that they have entered into a co-development and commercialization agreement for IntelGenx' first oral thin film product based upon the IntelGenx' proprietary VersaFilm technology. The product is intended for the rapid relief of migraine.
-
Ensign-Bickford Industries, Inc. Acquires Envirologix Inc.
SIMSBURY, CT--(Marketwire - August 30, 2010) - As part of its business growth and diversification strategy, Ensign-Bickford Industries, Inc. "EBI" announced today that its subsidiary, EB Analytics, Inc. has acquired EnviroLogix Inc. ("ELIX"). ELIX is a Portland, Maine-based developer and manufacturer of rapid QuickStixT and QuickScanT agricultural test kits and readers. The terms of the transaction were not released.
-
Spencer Pharmaceutical Appoints Critical Member to Its Scientific Advisory Board
BOSTON, MA--(Marketwire - August 30, 2010) - Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announces the appointment of Dr. Le Tien Canh, PhD to its Scientific Advisory Board.
-
BIOLASE to Discuss New Distribution Arrangement on Conference Call
BIOLASE to Host Call TODAY, August 30th at 11:00 a.m. E.D.T.
-
Portola Pharmaceuticals Announces That Phase 2 INNOVATE-PCI Trial With Elinogrel Achieved Objectives
Expects Commercial Partner Novartis to Initiate Phase 3 Trial by Q1 2011
-
Portola Pharmaceuticals Announces Presentation of New Pharmacodynamic Data From Phase 2 Trial of Investigational Factor Xa Inhibitor, Betrixaban
STOCKHOLM, SWEDEN--(Marketwire - August 29, 2010) - Portola Pharmaceuticals, Inc. today announced additional pharmacodynamic data from a pre-specified analysis of EXPLORE-Xa, a Phase 2 dose-finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. During a poster session at the European Society of Cardiology (ESC) Congress in Stockholm, Dr. Stuart Connolly, EXPLORE-Xa principal investigator and director, Division of Cardiology, McMaster University, Hamilton, Ontario, presented data from the analysis of three separate pharmacodynamic markers for anticoagulation (anti-Factor Xa units, thrombin generation and D-dimer) in plasma samples collected from patients enrolled in the EXPLORE-Xa clinical trial. The results showed a concentration dependent relationship and provided further evidence for the anticoagulant activity of betrixaban across all three doses studied in the clinical trial.
-
Immunovaccine Announces 2010 Second Quarter Results
HALIFAX, NOVA SCOTIA--(Marketwire - Aug. 27, 2010) - Immunovaccine Inc. (TSX VENTURE:IMV), a clinical stage vaccine company, today announced its operational and financial results for the second quarter ended June 30, 2010 ("Q2 Fiscal 2010").
|